This episode dives into ImmunityBio $IBRX and a biotech controversy where bold cancer cure claims collided with regulatory scrutiny. Built for investors, biotech traders, and market watchers, we break down FDA warning letters, drug approval limits, clinical hype, and stock drops. Expect deep dive analysis, biotech storytelling, and insights into regulatory risk, cancer therapies, and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
